The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Synagis was produced by AstraZeneca and AbbVie.
November also saw Sobi acquire rights to Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants from AstraZeneca. ... We completed the acquisition of Synagis in late January and are in the process of integrating
MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Synagis has been a nice earner for AZ, making almost $700m in revenues in 2017, but has started
Earlier this month, Sobi agreed to acquire the US rights to AstraZeneca’s respiratory syncytial virus (RSV) prevention drug Synagis (palivizumab) in a deal worth $1.5bn. ... Sobi's Guido Oelkers. “Gamifant will add significant strength to Sobi’s
s focus on Synagis will enable infants in the US to continue benefiting from this important treatment.”. ... The addition of Synagis will become an important strategic catalyst for Sobi’s future development and will form a powerful platform for
AZ sells a prophylactic RSV antibody - Synagis (palivizumab) - which brought in $677m in sales in 2016 despite being reserved for use in high-risk infants.
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...